Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  4D pharma plc    DDDD   GB00BJL5BR07

4D PHARMA PLC

(DDDD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
95.6(c) 93(c) 91.8(c) 93.6(c) 91.2 Last
1 278 670 1 293 356 1 291 263 1 232 581 64 420 Volume
-4.21% -2.72% -1.29% +1.96% -2.56% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -25,5 M -34,3 M -34,3 M
Net cash position 2020 5,50 M 7,40 M 7,40 M
P/E ratio 2020 -4,83x
Yield 2020 -
Sales 2021 15,4 M 20,7 M 20,7 M
Net income 2021 -13,8 M -18,6 M -18,6 M
Net Debt 2021 10,8 M 14,5 M 14,5 M
P/E ratio 2021 -8,91x
Yield 2021 -
Capitalization 123 M 166 M 166 M
EV / Sales 2020 -
EV / Sales 2021 8,69x
Nbr of Employees 127
Free-Float 59,3%
More Financials
Company
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally... 
More about the company
All news about 4D PHARMA PLC
11/274D PHARMA PLC : Files SEC Forms in Process to Gain NASDAQ Listing Following Merg..
BU
11/264D PHARMA : Files SEC Forms in Process to Gain NASDAQ Listing Following Merger w..
PU
11/094D PHARMA : presents new data from two MRx0518 clinical trials at the Society fo..
PU
11/094D PHARMA : Presents New Data from Two MRx0518 Clinical Trials at the Society fo..
BU
11/054D PHARMA : to Host Virtual KOL Event Reviewing New Data Presented at the Societ..
BU
11/054D PHARMA : to Host Virtual KOL Event Reviewing MRx0518 Data To Be Presented at ..
PU
10/074D PHARMA : announces topline results from Blautix® Phase II trial in irritable ..
PU
09/304D PHARMA : Interim results for the period ended 30 June 2020
PU
09/234D PHARMA : Directorate Change
PU
08/264D PHARMA : Clinical Update - comprehensive clinical benefit data from Part A of..
PU
07/064D PHARMA : Clinical Update - 4D pharma treats first cancer patients in Part B o..
PU
07/024D PHARMA : Clinical Update - Phase II COVID-19 study open for enrolment
PU
04/174D PHARMA : Clinical Update - Interim analysis of Blautix Phase II study data
PU
03/174D PHARMA : Additional Interim Clinical Data
PU
03/164D PHARMA : Participation in Chardan Conference
PU
More news
News in other languages on 4D PHARMA PLC

- No features available -

More news
Chart 4D PHARMA PLC
Duration : Period :
4D pharma plc Technical Analysis Chart | DDDD | GB00BJL5BR07 | MarketScreener
Technical analysis trends 4D PHARMA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 428,50 GBX
Last Close Price 93,60 GBX
Spread / Highest target 381%
Spread / Average Target 358%
Spread / Lowest Target 335%
EPS Revisions
Managers
NameTitle
Duncan Peyton Chief Executive Officer & Executive Director
Axel Gaston Glasmacher Non-Executive Chairman
Stephen Dunbar Finance Director
Alexander James Stevenson Executive Director & Chief Scientific Officer
Edgardo Baracchini Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
4D PHARMA PLC-6.40%166
GILEAD SCIENCES, INC.-6.34%76 628
VERTEX PHARMACEUTICALS3.62%58 951
REGENERON PHARMACEUTICALS32.85%53 359
WUXI APPTEC CO., LTD.67.28%39 880
BIONTECH SE250.30%29 157